JP2020527546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527546A5 JP2020527546A5 JP2019572724A JP2019572724A JP2020527546A5 JP 2020527546 A5 JP2020527546 A5 JP 2020527546A5 JP 2019572724 A JP2019572724 A JP 2019572724A JP 2019572724 A JP2019572724 A JP 2019572724A JP 2020527546 A5 JP2020527546 A5 JP 2020527546A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- amino acid
- acid sequence
- tlr7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 4
- 101800002011 Amphipathic peptide Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 238000006664 bond formation reaction Methods 0.000 claims 2
- 102000045715 human TLR7 Human genes 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- QETLKNDKQOXZRP-XTGBIJOFSA-N 5alpha-cholest-8-en-3beta-ol Chemical compound C([C@@]12C)C[C@H](O)C[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]21 QETLKNDKQOXZRP-XTGBIJOFSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 claims 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 claims 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010088535 Pep-1 peptide Proteins 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims 1
- 108010011110 polyarginine Proteins 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 claims 1
- 108010062760 transportan Proteins 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017902545 | 2017-06-30 | ||
| AU2017902545A AU2017902545A0 (en) | 2017-06-30 | A method of treatment | |
| PCT/AU2018/050667 WO2019000045A1 (en) | 2017-06-30 | 2018-06-29 | METHOD OF TREATMENT |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020527546A JP2020527546A (ja) | 2020-09-10 |
| JP2020527546A5 true JP2020527546A5 (enExample) | 2021-07-29 |
Family
ID=64740713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572724A Pending JP2020527546A (ja) | 2017-06-30 | 2018-06-29 | 治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11319343B2 (enExample) |
| EP (1) | EP3645030A4 (enExample) |
| JP (1) | JP2020527546A (enExample) |
| CN (2) | CN119548615A (enExample) |
| AU (1) | AU2018293925B2 (enExample) |
| WO (1) | WO2019000045A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119548615A (zh) * | 2017-06-30 | 2025-03-04 | 皇家墨尔本理工大学 | 一种治疗方法 |
| WO2022170396A1 (en) * | 2021-02-12 | 2022-08-18 | ViraLok Therapeutics Pty Ltd | Agents and methods for therapy and prophylaxis |
| CN114532296B (zh) * | 2021-12-14 | 2023-12-15 | 首都医科大学附属北京同仁医院 | NOX2基因缺陷rd1小鼠模型及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ525914A (en) | 1998-03-10 | 2004-03-26 | Genentech Inc | Novel polypeptides and nucleic acids encoding the same |
| ATE510850T1 (de) * | 2000-09-15 | 2011-06-15 | Coley Pharm Gmbh | Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten |
| KR20110039381A (ko) * | 2008-08-04 | 2011-04-15 | 이데라 파마슈티칼즈, 인코포레이티드 | 안티센스 올리고누클레오티드에 의한 톨-유사 수용체 7 발현의 조절 |
| US8940310B2 (en) * | 2010-06-16 | 2015-01-27 | Dynavax Technologies Corporation | Methods of treatment using TLR7 and/or TLR9 inhibitors |
| US20140378531A1 (en) * | 2012-02-01 | 2014-12-25 | New York University | Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors |
| US9228184B2 (en) * | 2012-09-29 | 2016-01-05 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
| WO2014174704A1 (ja) * | 2013-04-22 | 2014-10-30 | 国立大学法人東京大学 | 炎症性疾患の予防又は治療剤 |
| CN104211799B (zh) * | 2013-05-29 | 2017-12-26 | 成都渊源生物科技有限公司 | 人源egf结构域蛋白及其应用 |
| WO2015024669A1 (en) * | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Combination vaccine |
| US10308938B2 (en) * | 2014-06-20 | 2019-06-04 | Yale University | Compositions and methods to activate or inhibit toll-like receptor signaling |
| CN119548615A (zh) * | 2017-06-30 | 2025-03-04 | 皇家墨尔本理工大学 | 一种治疗方法 |
-
2018
- 2018-06-29 CN CN202411599223.4A patent/CN119548615A/zh active Pending
- 2018-06-29 US US16/624,367 patent/US11319343B2/en active Active
- 2018-06-29 AU AU2018293925A patent/AU2018293925B2/en active Active
- 2018-06-29 EP EP18823595.6A patent/EP3645030A4/en active Pending
- 2018-06-29 CN CN201880056934.3A patent/CN111417401A/zh active Pending
- 2018-06-29 JP JP2019572724A patent/JP2020527546A/ja active Pending
- 2018-06-29 WO PCT/AU2018/050667 patent/WO2019000045A1/en not_active Ceased
-
2022
- 2022-03-24 US US17/703,111 patent/US20220213143A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6995933B2 (ja) | インターロイキン23受容体の経口ペプチド阻害剤および炎症性腸疾患を処置するためのそれらの使用 | |
| US8785375B2 (en) | Cyclic antimicrobial peptides for treating bacterial infections | |
| JP2014525901A5 (enExample) | ||
| JP2005519041A5 (enExample) | ||
| JP2014524908A5 (enExample) | ||
| HU217843B (hu) | Paratiroid hormon (PTH) rokon polipeptidek, eljárások ezek előállítására és az ezeket tartalmazó gyógyszerek osteoporosis kezelésére | |
| JP2020527546A5 (enExample) | ||
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2011524420A5 (enExample) | ||
| HRP20170890T1 (hr) | Suagonisti glukagonskog/glp-1 receptora | |
| JP5753077B2 (ja) | 抗菌ペプチド多量体 | |
| HRP20210809T1 (hr) | Biciklični peptidni ligandi specifični za mt1-mmp | |
| KR20160063349A (ko) | 알파나선형 세포 투과 펩타이드 다합체,이의 제조방법 및 그 용도 | |
| JP2016518351A5 (enExample) | ||
| RU2011134596A (ru) | Аналоги оксинтомодулина | |
| WO2017114240A1 (zh) | 一种合成Etelcalcetide的方法 | |
| JP2012508698A5 (enExample) | ||
| US20160168203A1 (en) | Cyclic Antimicrobial Peptides | |
| JP2008522954A5 (enExample) | ||
| JP2017500316A5 (enExample) | ||
| JP2014519514A5 (enExample) | ||
| CN114644687A (zh) | 一种可拮抗rbm25蛋白rna结合活性的多肽rbip-21及其应用 | |
| JP2015533372A5 (enExample) | ||
| KR20170073585A (ko) | Cd44의 단리된 폴리펩타이드 및 이의 사용 | |
| KR20220139079A (ko) | 세포 투과성 펩타이드 변이체 및 이의 용도 |